TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04585490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2 on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVENIO ctDNA Surveillance Kit
Description: Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVENIO ctDNA Surveillance Kit
Description: Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: not to exceed 75mg IV on Day 1 of every 21-day cycle
Study: NCT05568836

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D supplementation
Description: Intervention group will receive a single IM injection of 300000 IU vitamin D

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: control group will receive nothing
Study: NCT05833516

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Catheterization
Description: The cardiac catheterization is an invasive procedure in which right or left radial artery of patient will be accessed to obtain cardiac angiogram. The study participants are both operators and patients by obtaining the amount of radiation they both were exposed in these two different arm techniques.~The patient will have to do nothing more than following the existing standard protocols which are followed nationwide. As, the radiation exposure to patients are already measured in the software itself. The operators however would be wearing radiation badges in 4 different anatomic locations to record radiation data for study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Catheterization
Description: The cardiac catheterization is an invasive procedure in which right or left radial artery of patient will be accessed to obtain cardiac angiogram. The study participants are both operators and patients by obtaining the amount of radiation they both were exposed in these two different arm techniques.~The patient will have to do nothing more than following the existing standard protocols which are followed nationwide. As, the radiation exposure to patients are already measured in the software itself. The operators however would be wearing radiation badges in 4 different anatomic locations to record radiation data for study.
Study: NCT05808335

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. Tenofovir (including salt-free or salt-modifying drugs)~2. Entecavir (including salt-free or salt-modifying drugs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. Tenofovir (including salt-free or salt-modifying drugs)~2. Entecavir (including salt-free or salt-modifying drugs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. Tenofovir (including salt-free or salt-modifying drugs)~2. Entecavir (including salt-free or salt-modifying drugs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. Tenofovir (including salt-free or salt-modifying drugs)~2. Entecavir (including salt-free or salt-modifying drugs)
Study: NCT04963673

Intervention type: OTHER
Intervention: calcineurin inhibitor dosage
Description: The dosage of calcineurin inhibitors will be done as usual by the toxicology pharmacology laboratory of the CHU Amiens-Picardie. If the patient does not object, the determination of protein-bound uremic toxins from the rest of the collected blood tube will be performed using high performance liquid chromatography.

Intervention type: OTHER
Intervention: calcineurin inhibitor dosage
Description: The dosage of calcineurin inhibitors will be done as usual by the toxicology pharmacology laboratory of the CHU Amiens-Picardie. If the patient does not object, the determination of protein-bound uremic toxins from the rest of the collected blood tube will be performed using high performance liquid chromatography.
Study: NCT06131541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autogenous tooth graft
Description: undemineralized autogenous tooth graft will augment the gap between the splitted ridge and the simultaneously \[laced implant fixture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autogenous bone graft
Description: autogenous bone graft will augment the gap between the splitted ridge and the simultaneously \[laced implant fixture
Study: NCT05414838

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin, Omega-3 and Vitamin-D (COD)
Description: Acumin™ Turmeric Complex (Dr. D's Ultra BioTurmeric) 500 mg daily (NPN 80087842)~Omega-3 supplements (combination of DHA and EPA) 900 mg daily (NPN 80019234)~Vitamin D3 supplements 2500 IU daily (NPN 80108995)
Study: NCT05406206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Arterial Infusion Chemotherapy
Description: HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m\*2 + 5-FU 2000 mg/m\*2, Q4W
Study: NCT05889819

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Almond orange potato cookies for stunted under-five children
Description: Trained enumerator distributed 50 g cookies three times a week during 30 days to the treatment group.~Anthropometry measurement: weight and height measured at pre study, during study (once a week), and post study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almond orange potato cookies for stunted under-five children
Description: Trained enumerator distributed 50 g cookies three times a week during 30 days to the treatment group.~Anthropometry measurement: weight and height measured at pre study, during study (once a week), and post study.
Study: NCT05412459

Intervention type: DRUG
Intervention: 99mTc-DARPinG3
Description: Diagnostic test (99mTc-DARPinG3-based SPECT) is used for the assessment of the effect of anticancer therapy.
Study: NCT05913206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambiguity
Description: The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambiguity
Description: The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambiguity
Description: The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
Study: NCT04287959

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula support
Description: airvo2 highflow devices will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula support
Description: airvo2 highflow devices will be used.
Study: NCT05258747

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablets, 150 mg
Description: Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablets, 150 mg
Description: Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia

Intervention type: DRUG
Group type: OTHER
Intervention: Lynparza® (olaparib) tablets 150 mg
Description: Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (DE).

Intervention type: DRUG
Group type: OTHER
Intervention: Lynparza® (olaparib) tablets 150 mg
Description: Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (DE).
Study: NCT06211062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floradapt Intensive GI
Description: one capsule daily for the eight week intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floradapt Intensive GI
Description: one capsule daily for the eight week intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule daily for the eight week intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule daily for the eight week intervention
Study: NCT05905991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Stress Resilience Training
Description: The ESRT intervention will consist of 1) five weekly one-hour sessions (in-person or virtual) led by a certified instructor; 2) smartphone-based exercises that bring informal practice into daily life; 3) videos on principles and concepts taught each week; and 4) meditation recordings of various lengths and styles supporting the prescribed daily practice of up to 20 min/day. Weekly didactic and experiential activities will cover mindfulness-based intervention concepts and skills, such as cultivating resilience, awareness of the body, managing thoughts, responding versus reacting, transforming circumstances, and advocacy through mindful communication. The ESRT smartphone app (Mindful Brian) houses all course materials (pre-class materials and post-class materials) and sends class reminders and messages. Considering nurses' shifts, ESRT will be offered in two separate sessions each week.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Stress Resilience Training
Description: The ESRT intervention will consist of 1) five weekly one-hour sessions (in-person or virtual) led by a certified instructor; 2) smartphone-based exercises that bring informal practice into daily life; 3) videos on principles and concepts taught each week; and 4) meditation recordings of various lengths and styles supporting the prescribed daily practice of up to 20 min/day. Weekly didactic and experiential activities will cover mindfulness-based intervention concepts and skills, such as cultivating resilience, awareness of the body, managing thoughts, responding versus reacting, transforming circumstances, and advocacy through mindful communication. The ESRT smartphone app (Mindful Brian) houses all course materials (pre-class materials and post-class materials) and sends class reminders and messages. Considering nurses' shifts, ESRT will be offered in two separate sessions each week.
Study: NCT05625581

Intervention type: DRUG
Intervention: tofacitinib
Description: All subjects were treated immediately after non randomized enrollment. The treatment scheme of the experimental group: glucocorticoid+tropitib; the treatment scheme of the control group: glucocorticoid+cyclophosphamide.

Intervention type: DRUG
Intervention: tofacitinib
Description: All subjects were treated immediately after non randomized enrollment. The treatment scheme of the experimental group: glucocorticoid+tropitib; the treatment scheme of the control group: glucocorticoid+cyclophosphamide.
Study: NCT05235763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity coach
Description: The activity coach educates the patient about physical activity, offers means of manually tracking physical activity, and provides trends of registered activity. Furthermore, it provides weekly summaries of registered physical activity and provides means of setting goals for the following week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham activity coach
Description: The visual appearance of Optilogg is changed as to make the patient aware that something has happened to it, hence not knowing if it is the real activity coach or not. No new functionality is added, however.
Study: NCT06341426

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Psychedelic Dose Psilocybin
Description: One psychedelic dose (1mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two Psychedelic Doses Psilocybin
Description: Two psychedelic doses (25 mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
Study: NCT04706741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Izokibep is an Interleukin-17 Inhibitor that will be administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Background Corticosteroid
Study: NCT06369025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children
Description: Interaction Competencies with Children - for Teachers (ICC-T) Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~Interaction Competencies with Children - for Parents (ICC-P) Core training components include parents-child interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the home
Study: NCT06437730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique:
Description: MTrPs points will be released with ischemic compression, position of ease will be acquired, and in the last METs will be performed. Ischemic compression applied through thumb on trigger point present in any muscle around the knee joint. Compression will be increased gradually until first resistance will feel and maintained until it resolves, further increases then until no tissue resistance will be felt under thumb. This process is maintained for 30sec and repeated 3-5 times per session. Positional release technique: after applying pressure on trigger point, patient will acquire position of ease that is maintained for 20 sec whether its extension or flexion of knee. This process is repeated 3-5 times per session. Muscle Energy Technique will be applied on the muscle in which isometric contraction is maintained for 7-10sec against 20-25% strength. After completion of muscular contraction, the limb is moved away for muscular stretch and then position is maintained for 30 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling:
Description: Dry needle will be targeting trigger points (TrPs) using in-and-out techniques such as 'pistoning' or 'sparrow pecking'. 0.25x25mm needle is inserted.~For vastus laterals patient is supine line with knee extended performing an isometric quadriceps contraction, maintaining a clean technique by using gloves and performing an alcohol wipe down bracket the tissue to be treated and inserting needle with direct approach towards the femur, performing pistoning. For vastus medialis patient is supine line with 30 degrees of knee flexion. A headless 0.25x25mm needle fixed between the fingers of non-dominant hand and inserted perpendicularly to the MTrPs with metacarpophalangeal flexion extension of 1st and 2nd fingers of dominant hand. For Gastrocnemius patient is prone lying and bolstered supported slight knee bend, for the upper part anterior medial approach is used and center of muscle belly slight medial anterior approach is used.
Study: NCT05522751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS
Description: Bilateral DBS electrodes will be implanted into the limbic pallidum of participants with severe alcohol use disorder and advanced but compensated liver disease.
Study: NCT05591469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IR Camera
Description: the respiration parameters are measured using an IR camera.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: the respiration parameters are measured using an electrical impedance tomograhy.
Study: NCT05913206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambiguity
Description: The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
Study: NCT05521295

Intervention type: OTHER
Intervention: no intervention
Description: no intervention in this study

Intervention type: OTHER
Intervention: no intervention
Description: no intervention in this study
Study: NCT05540743

Intervention type: DRUG
Group type: OTHER
Intervention: biologic DMARDs
Description: follow up the clinical response in Egyptian population to the drug
Study: NCT05645419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized chronoprevention
Description: Chronobiological variables: dynamic and static position of the planets of the solar system, moon, sun, constellations; angles/degrees of celestial objects above/below the horizon; angular interactions between celestial objects; the moment/time of the patients' birth; moment/time of MI occurrence; latitude / longitude of the place of birth of the patients, as well as the occurrence of MI (event); the degree of influence of celestial objects in relation to the constellations, where they were at a particular personal event / points of the patient.
Study: NCT06271603

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diagnosis based on deepLive™ LC-OCT device
Description: Management of BCC with an initial diagnosis based on the deepLive™ device using LC-OCT technology.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: diagnosis based on skin biopsy
Description: Control Arm: Standard management with an initial diagnosis based on skin biopsy
Study: NCT06215924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Kegel exercise
Description: In addition to the training given by the physician, patients will be taught the 'Reverse Kegel' exercise. The 'Reverse Kegel' exercise is an exercise that is used to relax the pelvic floor muscles. To practice the exercise, patients will be asked to lie in a supine position with a support under the knees. In this position, patients will be asked to relax the pelvic floor muscles while breathing through their nose, maintain this movement for 5 seconds, and tighten the pelvic floor muscles while exhaling. Patients will be advised to do this exercise for 5 sets, 10 repetitions during the day. On the day of the training, initial evaluations will be made to the patients before the exercise training is given. Evaluations will be repeated at the end of the second and fourth week.
Study: NCT05116865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-120 Dose 1
Description: Dose level 1 of HH-120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-120 Dose 1
Description: Dose level 1 of HH-120
Study: NCT06215924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postisometric Relaxation Technique
Description: In addition to training given by the physican, internal digital Postisometric Relaxation method will be applied to the patients in this group from the anal region. Application will be made to the muscles where muscle spasm, movement restriction and pain are detected. The patient will be asked to perform a contraction against the digital resistance with maximum force and maintain this contraction for 5 seconds, actively relax after 5 seconds. During relaxation, stretching will be applied for 30 seconds by digitally supporting the movement of the pelvic floor muscles. The process will be performed with 5 repetitions. The application will be made 2 days a week for 4 weeks. On the day of the training, initial evaluations will be made to the patients before the exercise training is given.Evaluations will be repeated at the end of the second and fourth week.
Study: NCT05700812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sound sparing levonorgestrel 52 mg IUD placement
Description: In phase one, the IUD will be placed in a standard fashion with the use of a uterine sound to obtain baseline data.~In the experimental phases of the study (phase 2 and 3) the levonorgestrel 52 mg IUD will be placed without the use of a uterine sound. In phase 2 the IUD will be placed under abdominal ultrasound guidance. In phase 3 the IUD will be placed without abdominal ultrasound guidance.
Study: NCT05022524

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acetate (Apple Cider Vinegar)
Description: Consumer-grade apple cider vinegar (ACV) capsules will have extra enteric coating applied for delivery further into the GI tract.